VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2018 | The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer

In this video, Kathleen Moore, MD, principle investigator, from the Stephenson Cancer Center, Oklahoma City, OK, talks about the implications of the SOLO-1 trial (NCT01844986) and the necessity for earlier screening of BRCA in order to guide therapy. Dr Moore focuses on the PAOLA-1 trial (NCT02477644) that looks at olaparib combined with bevacizumab for patients with ovarian cancer without having to select for BRCA mutation, which could potentially result in increased accessibility to PARP inhibitors and bevacizumab. Dr Moore was speaking from the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter